Day: September 16, 2021

SEATTLE, Sept. 16, 2021 (GLOBE NEWSWIRE) — Homeowners of America (HOA), a property and casualty insurance provider and subsidiary of Porch Group, Inc. (“Porch” or “the Company”) (NASDAQ: PRCH), today announced the launch of service in Nevada. Porch, a leading vertical software company reinventing the home services and insurance industries, completed its acquisition of HOA in April 2021 with plans to drive growth in HOA’s current markets and begin national expansion. With the addition of Nevada, HOA now operates in eight states. This expansion furthers Porch’s reach for its InsurTech business, now offering a competitively priced homeowners insurance product to homebuyers, homeowners and HOA agents. “Introducing the insurance offerings of HOA to the Nevada market further demonstrates our commitment to the continued growth...

Final results from completed Phase 1b trial in patients with small cell lung cancer (SCLC) receiving second-line topotecan demonstrated ALRN-6924’s ability to reduce neutropenia, thrombocytopenia and anemia caused by chemotherapy, as well as the need for transfusions Preliminary results from ongoing Phase 1 pharmacology study in healthy volunteers confirmed ALRN-6924’s optimal dose (0.3 mg/kg), its mechanism of action, and demonstrated time to onset, duration and magnitude of its pharmacodynamic effects These new data will inform the design of anticipated future clinical studies to investigate ALRN-6924 as a chemoprotective agent in other p53-mutated cancers and with other types of chemotherapy A precision medicine-based chemoprotective agent, ALRN-6924 is designed to selectively activate p53 in normal cells, thereby upregulating p21,...

CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced 23 data presentations at the Infectious Disease Society of America (IDSA) IDWeekTM 2021, taking place virtually from September 29 – October 3, 2021. Presentations will showcase in vitro and in vivo studies of Spero’s oral antibiotic investigational candidate tebipenem HBr for the treatment of adults with complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) and highlight additional research on the epidemiology and management of cUTI. Presentations pertaining to tebipenem HBr and the epidemiology...

Research demonstrates the ability of Adaptive’s immune medicine platform to distinguish natural infection from vaccine response and the ability to detect prior infection nearly 12 months after initial diagnosis in some patients SEATTLE, Sept. 16, 2021 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, will be presenting data from two studies employing Adaptive’s immune medicine platform to understand the T-cell response to SARS-CoV-2 infection at IDWeek 2021, which takes places virtually from September 29-October 3, 2021. T-cell responses are more durable and broader than antibody responses, recognizing many different parts of the SARS-CoV-2 virus,...

BALA CYNWYD, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in 1×1 investor meetings at the SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1×1 Event. The event is taking place virtually September 22-23, 2021. About Larimar Therapeutics Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the U.S. as a potential treatment for Friedreich’s ataxia. Larimar also plans to use its intracellular delivery...

CHICAGO, Sept. 16, 2021 (GLOBE NEWSWIRE) — Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer, announced today that Modern Healthcare had selected it as one of the 2021 Best Places to Work in Healthcare. The complete list of this year’s winners, in alphabetical order, is available at ModernHealthcare.com/bestplaceslist. Modern Healthcare will publish a special supplement featuring a ranked list of all the winners along with the September 20 issue of Modern Healthcare. “One year into the pandemic, we’ve seen the industry transform to meet the needs of its patients and employees,” said Aurora Aguilar, Modern Healthcare’s...

TORONTO, Sept. 16, 2021 (GLOBE NEWSWIRE) — Jade Power Trust (“Jade Power” or the “Trust”) (TSXV:JPWR.UN) is pleased to announce that the TSX Venture Exchange (the “TSX-V”) has accepted the Trust’s application for its previously announced normal course issuer bid (the “NCIB”) for up to 11,560,812 trust units (“Units”) in the capital of the Trust, representing 5% of the issued and outstanding Units, over a 12-month period. The NCIB will commence on September 17, 2021 and continue until September 16, 2022 (the “Termination Date”) or earlier in the event that the Trust has acquired the maximum number of Units that it may purchase under the NCIB or if the Trust determines that it is appropriate to terminate the NCIB prior to the Termination Date. The actual number of Units that will be purchased under the NCIB, if any, and the timing...

SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that company management will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference at 2:40 p.m. ET on Tuesday, September 28, 2021. eFFECTOR will also host investor meetings throughout the conference. A live webcast of the fireside chat will be available on the “Events and Presentation” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit investors.effector.com. About eFFECTOR Therapeutics eFFECTOR is a clinical-stage biopharmaceutical company focused on pioneering the...

      NUC-3373 Continues to Demonstrate Encouraging Efficacy Signals and a Favorable Safety Profile in Patients with Advanced Colorectal Cancer       NUC-3373 Phase 1 Study Demonstrated Encouraging Efficacy Signals and a Favorable Safety Profile in Patients with Advanced Solid Tumors and Established the Recommended Monotherapy Phase 2 Dose       NUC-7738 Continues to Show Anti-cancer Activity and Prolonged Disease Control with a Favorable Tolerability and Pharmacokinetic Profile in Patients with Advanced Solid Tumors EDINBURGH, United Kingdom, Sept. 16, 2021 (GLOBE NEWSWIRE) — NuCana plc (NASDAQ: NCNA), announced the presentation of four posters at the European Society for Medical Oncology (ESMO) Congress 2021. The Company presented additional data from the ongoing Phase 1b/2 study of NUC-3373 in combination with standard therapies...

WILMETTE, Ill., Sept. 16, 2021 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced its Phase 1b open-label dose-escalation clinical trial of camsirubicin in the US is active and recruiting patients. The trial is evaluating the safety and anti-tumor activity of increasing doses of camsirubicin in combination with growth factor support (pegfilgrastim/G-CSF) for the treatment of advanced soft tissue sarcoma (ASTS). “This trial initiation marks a pivotal moment in the development of camsirubicin. The goal is to determine whether escalating doses of camsirubicin result in an increased anti-cancer effect in patients with ASTS, while also maintaining...